Pureos Bioventures has backed five spinouts so far from its multi-corporate-backed, biotech-focused fund.
Switzerland-based venture capital firm Pureos Bioventures closed a $170m inaugural fund yesterday backed by an unnamed drug manufacturing firm and multiple pharmaceutical and biotech companies.
Undisclosed well as a fund-of-funds, institutional investors and family offices have also invested in the fund, which will focus on the biopharmaceutical sector.
Spinouts make up five of seven companies backed by Pureos’s fund to date.
They include liver disease drug developer Alentis Therapeutics, which extends research from University of Strasbourg, Inserm and French…
